- Home
- ENTX vs UAC Comparison
ENTX vs UAC Comparison
Compare ENTX & UAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENTX | UAC |
|---|---|---|
| Founded | 2010 | 2025 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 137.6M |
| IPO Year | 2015 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ENTX | UAC |
|---|---|---|
| Price | $2.78 | $9.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 2.0K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $42,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $41.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $9.51 |
| 52 Week High | $4.20 | $9.99 |
Technical Indicators
Market Signals| Indicator | ENTX | UAC |
|---|---|---|
| Relative Strength Index (RSI) | 60.29 | 53.57 |
| Support Level | $1.26 | $9.51 |
| Resistance Level | $3.22 | $9.97 |
| Average True Range (ATR) | 0.36 | 0.02 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 40.43 | 44.44 |
Price Performance
Historical ComparisonAbout ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.